blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3549580

EP3549580 - ENDOPLASMIC RETICULUM-TARGETING NANOVEHICLES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.05.2025
Database last updated on 21.03.2026
FormerThe patent has been granted
Status updated on  24.05.2024
FormerGrant of patent is intended
Status updated on  31.01.2024
FormerRequest for examination was made
Status updated on  12.06.2020
FormerThe application has been published
Status updated on  06.09.2019
Most recent event   Tooltip23.01.2026Lapse of the patent in a contracting state
New state(s): IE		published on 25.02.2026  [2026/09]
Applicant(s)For all designated states
National Cheng Kung University
1 University Road
Tainan / TW
[2024/09]
Former [2019/41]For all designated states
National Cheng Kung University
1 University Road
Tainan City 70101 / TW
Inventor(s)01 / Shieh, Chi-Chang
1 University Road
Tainan / TW
02 / Yen, Chia-Liang
1 University Road
Tainan / TW
03 / Shieh, Dar-Bin
1 University Road
Tainan / TW
04 / Jiang, Si-Tse
1 University Road
Tainan / TW
 [2019/41]
Representative(s)Cabinet Becker et Associés
25, rue Louis le Grand
75002 Paris / FR
[2019/41]
Application number, filing date19156311.308.02.2019
[2019/41]
Priority number, dateUS201862652502P04.04.2018         Original published format: US 201862652502 P
[2019/41]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3549580
Date:09.10.2019
Language:EN
[2019/41]
Type: A3 Search report 
No.:EP3549580
Date:25.12.2019
Language:EN
[2019/52]
Type: B1 Patent specification 
No.:EP3549580
Date:26.06.2024
Language:EN
[2024/26]
Search report(s)(Supplementary) European search report - dispatched on:EP25.11.2019
ClassificationIPC:A61K31/12, A61K45/06, A61K31/05, A61K31/365, A61K31/407, A61K31/55, A61K31/58, A61K31/7048, A61P43/00, A01K67/027
[2019/41]
CPC:
A61K45/06 (EP,US); A61K9/5153 (KR); A61K47/6925 (US);
A01K67/0275 (US); A01K67/0276 (KR); A01K67/0278 (EP,CN,US);
A61K31/05 (EP,US); A61K31/12 (EP,KR,US); A61K31/122 (KR);
A61K31/365 (EP,KR,US); A61K31/407 (EP,KR,US); A61K31/55 (EP,US);
A61K31/58 (EP,US); A61K31/7048 (EP,US); A61K36/06 (US);
A61K36/22 (US); A61K36/23 (US); A61K36/9062 (US);
A61K36/9066 (US); A61K45/00 (CN); A61K47/24 (CN);
A61K47/32 (CN); A61K47/34 (CN); A61K47/36 (CN);
A61K47/42 (CN); A61K47/593 (US); A61K47/64 (KR);
A61K9/0056 (US); A61P1/00 (CN); A61P1/16 (CN);
A61P11/00 (CN); A61P17/00 (CN); A61P19/08 (CN);
A61P21/00 (CN); A61P25/00 (CN); A61P25/28 (CN);
A61P27/02 (CN); A61P29/00 (KR); A61P3/06 (CN);
A61P3/10 (CN); A61P35/00 (CN); A61P37/00 (US);
A61P37/02 (KR); A61P43/00 (EP,CN,US); A61P5/06 (CN);
A61P5/14 (CN); A61P7/00 (CN); A61P7/04 (CN);
A61P7/06 (CN); A61P7/10 (CN); A61P7/12 (CN);
A61P9/00 (CN); A61P9/10 (CN); A61P9/14 (CN);
A01K2207/15 (CN); A01K2217/072 (EP); A01K2217/075 (KR,US);
A01K2217/206 (US); A01K2227/105 (EP,CN,KR,US); A01K2267/0306 (CN,US);
A01K2267/0331 (KR); A01K2267/0387 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/29]  
Former [2019/41]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ENDOPLASMATISCHE, AUF DAS RETIKULUM GERICHTETE NANOVEHIKEL[2019/41]
English:ENDOPLASMIC RETICULUM-TARGETING NANOVEHICLES[2019/41]
French:NANOVÉHICULES ENDOPLASMIQUES CIBLANT LE RÉTICULUM[2019/41]
Examination procedure08.06.2020Amendment by applicant (claims and/or description)
08.06.2020Examination requested  [2020/29]
08.06.2020Date on which the examining division has become responsible
01.02.2024Communication of intention to grant the patent
17.05.2024Fee for grant paid
17.05.2024Fee for publishing/printing paid
17.05.2024Receipt of the translation of the claim(s)
Opposition(s)27.03.2025No opposition filed within time limit [2025/23]
Fees paidRenewal fee
25.02.2021Renewal fee patent year 03
27.06.2022Renewal fee patent year 04
27.03.2023Renewal fee patent year 05
27.02.2024Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
28.02.202204   M06   Fee paid on   27.06.2022
28.02.202305   M06   Fee paid on   27.03.2023
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ26.06.2024
HR26.06.2024
MC26.06.2024
PL26.06.2024
RO26.06.2024
SK26.06.2024
SM26.06.2024
NO26.09.2024
RS26.09.2024
GR27.09.2024
IS26.10.2024
IE08.02.2025
CH28.02.2025
[2026/09]
Former [2025/48]CZ26.06.2024
HR26.06.2024
MC26.06.2024
PL26.06.2024
RO26.06.2024
SK26.06.2024
SM26.06.2024
NO26.09.2024
RS26.09.2024
GR27.09.2024
IS26.10.2024
CH28.02.2025
Former [2025/43]CZ26.06.2024
HR26.06.2024
MC26.06.2024
PL26.06.2024
RO26.06.2024
SK26.06.2024
SM26.06.2024
NO26.09.2024
RS26.09.2024
GR27.09.2024
IS26.10.2024
Former [2025/10]CZ26.06.2024
HR26.06.2024
PL26.06.2024
RO26.06.2024
SK26.06.2024
SM26.06.2024
NO26.09.2024
RS26.09.2024
GR27.09.2024
IS26.10.2024
Former [2025/09]HR26.06.2024
PL26.06.2024
NO26.09.2024
RS26.09.2024
GR27.09.2024
IS26.10.2024
Former [2025/08]HR26.06.2024
PL26.06.2024
NO26.09.2024
RS26.09.2024
GR27.09.2024
Former [2024/49]HR26.06.2024
NO26.09.2024
RS26.09.2024
GR27.09.2024
Former [2024/47]HR26.06.2024
NO26.09.2024
GR27.09.2024
Former [2024/46]HR26.06.2024
NO26.09.2024
Documents cited:Search[A] WO03049717  (PANACEA PHARM LLC et al.)
 [A] WO2014036534  (UNIV NORTH TEXAS et al.)
 [A]   HUANG Y F ET AL: "Thapsigargin and flavin adenine dinucleotide ex vivo treatment rescues trafficking-defective gp91phox in chronic granulomatous disease leukocytes", FREE RADICAL BIOLOGY AND MEDICINE, ELSEVIER INC, US, vol. 47, no. 7, 1 October 2009 (2009-10-01), pages 932 - 940, XP026542080, ISSN: 0891-5849, [retrieved on 20090722], DOI: 10.1016/J.FREERADBIOMED.2009.06.037

DOI:   http://dx.doi.org/10.1016/j.freeradbiomed.2009.06.037
 [A]   ALESSANDRO PARODI ET AL: "Enabling cytoplasmic delivery and organelle targeting by surface modification of nanocarriers", NANOMEDICINE, vol. 10, no. 12, 1 July 2015 (2015-07-01), GB, pages 1923 - 1940, XP055611683, ISSN: 1743-5889, DOI: 10.2217/nnm.15.39

DOI:   http://dx.doi.org/10.2217/nnm.15.39
by applicant  HOLLAND, HEMATOL. ONCOL. CLIN. NORTH AM., vol. 27, 2013, pages 89 - 99
   O'NEILL ET AL., REDOX BIOL., vol. 6, 2015, pages 135 - 156
   ROOS, BR. MED. BULL., vol. 118, 2016, pages 50 - 63
   HUANG ET AL., INFLAMM. BOWEL DIS., vol. 22, 2016, pages 2794 - 280
   HUANG ET AL., ANTIOXID. REDOX SIGNAL., vol. 23, 2015, pages 973 - 984
   NGUYEN ET AL., FRONT. CELL INFECT. MICROBIOL., vol. 7, 2017, pages 373
   LIN ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1586, 2002, pages 275 - 286
   HUANG ET AL., FREE RADICAL BIOL. MED., vol. 47, 2009, pages 932 - 940
   EGAN ET AL., SCIENCE, vol. 304, 2004, pages 600 - 602
   GUPTA ET AL., MOL. NUTR. FOOD RES., vol. 57, 2013, pages 1510 - 1528
   LIU ET AL., EVID. BASED COMPLEMENT. ALTEMAT. MED., 2016, pages 7831282
   REUTER ET AL., BIOCHEMICAL PHARMACOLOGY, vol. 76, 2008, pages 1340 - 1351
   ZHONG ET AL., J. NANOBIOTECHNOLOGY, vol. 8, 2010, pages 6
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.